Join the first ever BioStock Executive Bootcamp Day!

BioStock hosts its 7th annual Life Science Summit on November 20-21. For the first time, we are proud to invite C-level life science executives to a preparatory afternoon on November 19 – BioStock Executive Bootcamp Day!

The day offers C-level executives of growth stage life science companies valuable insights in IP, clinical trials, partnering potential and the importance of a qualified board through four sessions.

“How to make your company more attractive to investors: The IP perspective”,  with Potter Clarkson 

If you are seeking investment, your IP is crucial.

We have seen valuations drop by as much as 70% when investors spot weaknesses in an IP portfolio. More worryingly, we have also seen a significant number of investors walk away entirely if your pitch doesn’t cover everything they want to see.

To make sure this doesn’t happen, we will share what we have learned investors want to see so you can give your business the best possible chance of securing the investment you need to take the next step and support the strongest possible exit.

This session will look at:

  • How best to present your IP in line with your business plan and value proposition (and how best to showcase your IP in your data room)
  • How to set your revenue model out clearly so investors immediately see how your IP will deliver the required financial return
  • Proving you have freedom to operate by performing/paying for the level of FTO that is actually required

“Utilising CRO’s for effective planning and execution of Clinical Development”, with Aixial Group

You might have an idea about the clinical pathway for your candidate or product, but have you considered all alternatives from a strategic perspective? What would be an optimal study design and how can you ensure that it aligns with the regulators’ expectations?

This session will cover both preparations for, and execution of, clinical trials. We will discuss how to understand the regulators and markets you are facing, and reverse engineering of development strategies to increase chances of approval.

“Big Pharma’s Due Diligence: How to be prepared for it”, with Novo Nordisk

An interactive session to discuss and learn about how to best prepare for that all important Pitch and Due Diligence with a potential big pharma partner. This session will provide you with tips on what, when and how to reveal the scientific information in your hands to conclude on a successful Evaluation, Due Diligence and Negotiations with a large pharma company.

“Building Better Boards”, a session hosted by VILDA & Amrop

VILDA and Amrop, in collaboration with BioStock, invites you to an exclusive session on the theme of “Building Better Boards” targeting the transformation from a scientifically to a commercially weighted company. The session will focus on the following main topics:

  • The role of the board, and what a well-functioning board looks like
  • How to build a strong and effective board
  • Joining a board – what to think about when starting as a non-executive director

All with perspective and insight from 5 selected professional board members and executives, namely:

  • Ingrid Atteryd Heiman, Board Professional in Life Science 
  • Christina Herder, Board Professional in Life Science 
  • Martin Jönsson CEO Alzecure
  • Cecilia Callmer Partner, Executive Search, Board & Leadership Advisory, Amrop 
  • Peter Benson, Board Professional and Entrepreneur

The afternoon will start at Inspira and finish up at Bistro Merge. Both venues are located at Medicon Village, Lund

SCHEDULE NOVEMBER 19

BioStock Executive BootCamp Day


12:30

Meet-and-Greet


13:00

How to make your company more attractive to investors: The IP perspective
Benjamin Hoffman, Partner and Patent Attorney at Potter Clarkson
Lars Karnøe, Partner and Attorney at Potter Clarkson


13:45

Coffee Break


14:00

Utilising CRO’s for effective planning and execution of Clinical Development
Ashley Hunter, Senior Director, Clinical Operations and Delivery &
Anna Yanaeva, Senior Director, Business Developmentat, at Aixial Group


14:45

Coffee Break


15:00

Big Pharma’s Due Diligence: How to be prepared for it
Anu Balendran, Senior Director, Due Diligence, Research & Early Development at Novo Nordisk


15:45

Transition to Bistro Merge


16:00

Building Better Boards

Featured speakers:
Ingrid Atteryd Heiman, Board Professional in Life Science
Christina Herder, Board Professional in Life Science
Martin Jönsson CEO Alzecure
Cecilia Callmer Partner, Executive Search, Board & Leadership Advisory, Amrop
Peter Benson, Board Professional and Entrepreneur


17:30

After Work

Please note that registration is mandatory. Apply to participate below.
Due to limited seats, priority goes to C-level executives in the life science industry.